Innovation in life sciences in India – current state and future imperatives

The business model that has powered the pharma industry over the last few decades has shown signs of fatigue and is now evolving into something new. This change is being driven by skyrocketing costs, a lack of breakthrough innovation, and intense competition, combined with a much greater requirement from global healthcare systems for better patient outcomes at a lower cost.

Research from KPMG indicates that the return on Research and Development expenditure within the pharmaceutical industry has been falling, from an industry average of approximately 20 per cent 20 years ago, to barely above 10 per cent today. It is evident that the industry needs to switch from a product push to a more service oriented model, where the needs of the patient are at the very epicentre. Not only will this lead to new revenue streams, satisfying the increasing demands of corporate shareholders, but it will also help create a better understanding of medical conditions, allowing for more innovative and patient-centred treatments.

We have seen a recent acceleration of corporate M&A in the Life Sciences sector that is reshaping the industry across the globe. Companies are consolidating into a smaller number of therapeutic areas of strength, or divesting in areas of weakness. Collaboration between pharmaceutical firms is critical if the industry is to successfully transform. Initiatives such as clinical trial data sharing between organisations, where an independent third-party acts as a gatekeeper to access requests, are starting to gain momentum. And open-source R&D is already speeding up discoveries for the treatment of various diseases.

Despite many headwinds, the life science industry is well placed to benefit from two key factors: an ever increasing demand for healthcare, and the many exciting new advances in medical research. To capitalise, the industry must be more disciplined than ever before, find better ways to collaborate across the whole healthcare ecosystem and focus on areas where value for patients can be clearly demonstrated.

Write to us at to get a copy of this report.

Insights into the Biosimilars market: An overall perspective

Considered a major hope for the effective treatment of several diseases that have no cure till date, development of biotech medicines has been embraced as a core research and development area across some of the largest and populous economies in the world.

With rising healthcare costs, the impending patent cliff and a relatively slow pace of development of generics, development of biologics is regarded as one of the most promising frontiers in pharmacotherapy, with biologics expected to have a global market to the tune of US$ 3.7 billion by 2015.

Benchmarking against the performance and regulation in the leading nations of the world indicates that the value generation opportunity of biosimilars is dependent on several factors, including speed of development, clarity in regulation, ease of access and particularly the roles of all stakeholders. Potential aside, there remain regulatory challenges, success of clinical trials as well as safety and efficacy tests which are characterized by a huge investment outlay.

Write to us at to get a copy of this report.

Trips And Innovation Trends In The Indiab Biopharmaceutical Industry

To many industry experts within and outside the Indian pharmaceutical industry, the recent changes to the Indian patent law is a watershed event this is likely to have long term implications on the competitiveness of the industry. Yet even after seven years from the event little is known about how the changes influenced the industry. Many domestic firms believe that the new patent law is likely to halt their aspirations to become a dominant generic player while many multinational firms believe that the new law will open up their firms to new market opportunities well beyond those in the developed world. In this report we paint a broad brush on how the most recent changes to the Indian patent law influenced firm strategies and the competitiveness of local players in the industry. Given the current sets of firm capabilities that Indian and foreign firms are armed with, we believe the new patent law is likely to result in both these categories of firms reconfiguring their strategies. Also, how firms adapt to the new reality will determine their performance in this new era. We present our broad findings and our conjecture on the long term implications of the new patent law on the Indian pharmaceutical industry.

Write to us at to get a copy of this report.

The Asian Promise
Key trends and alliances in biotechnology during 2010

The global biotechnology sector has witnessed various regional shifts – with the West emerging as the land of capital and Asia shifting strategically from a mere outsourcing destination to a centre of innovation. In this paper, we attempt to bring out key drivers of this regional transformation in Asia and analyse this era of research-based alliances.

Alliances that reward bio-innovation have been the name of the game in the global markets. The leaders of this bio-frenzy in the Asian region have been Japan, China and India, witnessing some of the largest deals of varying types: the traditional biotechpharma deals, biotech-biotech deals and ubiquitous M&As. The big pharma push towards generics in emerging markets; non-exclusive licensing arrangements in biotech; investment capital provided by the West; faith in the discovery of biosimilars; and milestone-based alliances have been some of the innovative outcomes of this year’s bio-deal monitor.

Asia promises to become a biotechnology hub and this is made evident by the growing number of cross border collaborations in this sector since 2010. The region’s thriving biotechnology sector has been driving innovation on its own over the last decade – Asia is now set to be a significant centre of developmental expertise. A fact now acknowledged and respected by the world, evident in the flurry of collaborations in 2010.

Write to us at to get a copy of this report.